Read by QxMD icon Read


Ichiro Otani, Shiro Oka, Shinji Tanaka
A 72-year-old woman with ulcerative colitis was referred to our hospital because of refractory diarrhea. Although she had been treated with prednisolone 12.5 mg/day and mesalazine suppositories 1 g/day, her watery diarrhea persisted. Colonoscopy was undergone 30 days after she started administration of mesalazine suppositories, and showed granularity of the mucosa with little erythematous appearance in the entire colon with endoscopic Mayo score 1. Double-contrast small-bowel radiography showed a rough mucosal surface in the terminal ileum...
October 15, 2016: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
Dan Turner, Baruch Yerushalmi, Michal Kori, Efrat Broide, Yael Mozer-Glassberg, Ron Shaoul, Kaija-Leena Kolho, Eyal Shteyer, Hussein Shamaly, Oren Ledder, Shlomi Cohen, Sarit Peleg, Avi On, Arie Levine
BACKGROUND: Trials in adults suggested once-daily (QD) dosing of 5-ASA may be as or more effective as twice-daily (BID) dosing in ulcerative colitis (UC). In this induction of remission, investigator-blinded, randomized-controlled-trial we aimed to compare effectiveness and safety of once vs. twice daily mesalazine (Pentasa®), in paediatric UC. METHODS: Children, 4-18 years with a PUCAI ( Paediatric Ulcerative Colitis Activity Index) of 10-55 points at inclusion, were randomized in blocks of 6 with blinded allocation to QD or BID mesalamine using a weight-based dosing table...
October 3, 2016: Journal of Crohn's & Colitis
Wen-Zhen Zhao, Na Diao, Yi-Xiu Gu, Xiao-Tong Zhu, Ming-Song Li
OBJECTIVE: To investigate the efficacy of Yunnan Baiyao (YNBY)as an adjuvant treatment of active ulcerative colitis. METHODS: A total of 221 patients with active ulcerative colitis were randomized into YNBY group (78 cases) and control group (143 cases). The patients were followed up for 26 weeks and time of remission and serological data (WBC, HGB, PLT, and CRP) were recorded. RESULTS: The patients receiving YNBY as an adjuvant therapy had a median remission time of 9 weeks (95% CI: 8...
August 20, 2016: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
G Chawdhary, S Hussain, R Corbridge
Central skull-base osteomyelitis (CSBO) is a rare life-threatening infection, usually resulting from medial spread of necrotising otitis externa. Here, we describe a case with no identifiable source of infection, causing a delay in diagnosis. An 80-year-old man with Crohn's disease treated with mesalazine presented with collapse and tonic-clonic seizure. Computed tomography and magnetic resonance imaging showed a nasopharyngeal mass that was initially thought to be a neoplasm. Awaiting formal biopsy, he represented with collapse and repeat imaging showed features of abscess formation...
September 23, 2016: Annals of the Royal College of Surgeons of England
G D'Haens
BACKGROUND: Oral corticosteroids are the mainstay treatment for induction of ulcerative colitis remission in patients failing or intolerant to aminosalicylate therapy, but the poor tolerability profile of these drugs limits their usefulness. Second-generation, gut-selective corticosteroids may offer a safe alternative to systemic agents. AIM: To review the efficacy and safety of systemic and second-generation oral corticosteroids for the induction of remission in ulcerative colitis...
November 2016: Alimentary Pharmacology & Therapeutics
Takuya Yoshino, Makoto Sono, Shujiro Yazumi
BACKGROUND: Patients with refractory-ulcerative colitis (UC) require therapy escalation. Sulfasalazine (SASP) could deliver a high concentration of 5-aminosalicylic acid to the colon. The usefulness of SASP for refractory-UC patients, however, is unclear. AIM: The aim was to evaluate the usefulness of SASP for refractory-UC patients. METHOD: We retrospectively analysed 36 (11.4%) of 316 patients with refractory-UC who had been treated with SASP...
2016: BMJ Open Gastroenterology
Vincenzo Davide Palumbo, Marcello Romeo, Antonella Marino Gammazza, Francesco Carini, Provvidenza Damiani, Giuseppe Damiano, Salvatore Buscemi, Attilio Ignazio Lo Monte, Alice Gerges-Geagea, Abdo Jurjus, Giovanni Tomasello
AIM: Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity...
September 2016: Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
Antonio Tursi, Marcello Picchio, Walter Elisei, Francesco Di Mario, Carmelo Scarpignato, Giovanni Brandimarte
BACKGROUND: Management of diverticular disease (DD) remains a point of debate. GOALS: To investigate the current opinion of participants of the 2nd International Symposium on Diverticular Disease, on real-life management of patients with DD of the colon. STUDY: Twelve questions were aimed at the diagnosis, treatment, and management options for diverticulosis and symptomatic DD. RESULTS: In total, 115 surveys from 8 European Countries were filled out...
October 2016: Journal of Clinical Gastroenterology
Rudi De Bastiani, Guido Sanna, Pierluigi Fracasso, Maurizio D'Urso, Edoardo Benedetto, Antonio Tursi
GOALS: To investigate the current opinion of Italian general practitioners (GPs) on the management of patients with diverticular disease (DD) of the colon. BACKGROUND: The management of DD remains a point of debate, and guidelines are not uniform in their advice. STUDY: A web-based survey was conducted among Italian GPs. Twelve questions were aimed at the diagnosis, treatment, and management options for diverticulosis and symptomatic DD. RESULTS: In total, 245 surveys were filled out...
October 2016: Journal of Clinical Gastroenterology
Marcello Picchio, Walter Elisei, Giovanni Brandimarte, Francesco Di Mario, Peter Malfertheiner, Carmelo Scarpignato, Antonio Tursi
BACKGROUND: Symptomatic uncomplicated diverticular disease (SUDD) is a common gastrointestinal disease, because it affects about one fourth of the patient harboring colonic diverticula. GOAL: To assess the effectiveness of mesalazine in improving symptoms (namely abdominal pain) and in preventing diverticulitis occurrence in patients with SUDD. STUDY: Only randomized clinical trials (irrespective of language, blinding, or publication status) that compared mesalazine with placebo or any other therapy in SUDD were evaluated...
October 2016: Journal of Clinical Gastroenterology
Giovanni Barbara, Cesare Cremon, Maria R Barbaro, Lara Bellacosa, Vincenzo Stanghellini
Colonic diverticulosis is an increasingly common condition in Western industrialized countries. About 20% of patients develop symptoms, including abdominal pain, bloating, changes in bowel habits, and, eventually, diverticulitis or other complications. The management of symptomatic uncomplicated diverticular disease (SUDD) and the prevention of acute diverticulitis remains a challenge for the clinician. The rationale for the use of aminosalicylates, such as mesalazine, is based on the assumption of low-grade inflammation in SUDD and symptoms generation, whereas an overt inflammation may induce diverticulitis in patients with diverticular disease...
October 2016: Journal of Clinical Gastroenterology
Antonio Tursi, Giovanni Brandimarte, Francesco Di Mario, Walter Elisei, Carmelo Scarpignato, Marcello Picchio
Diverticular inflammation and complication assessment (DICA) endoscopic classification has been recently developed for patients suffering from diverticulosis and diverticular disease. Its predictive value in those patients was recently retrospectively assessed. For each patient, the following parameters were recorded: age, severity of DICA, presence of abdominal pain, C-reactive protein, fecal calprotectin test (if available) at the time of diagnosis, months of follow-up, therapy taken during the follow-up to maintain remission (if any), occurrence/recurrence of diverticulitis, and need of surgery...
October 2016: Journal of Clinical Gastroenterology
Martha Moheb Morcoss, Nada Sayed Abdelwahab, Nouruddin Wagieh Ali, Mohammed Taha Elsaady
Two selective spectrophotometric and TLC-densitometric methods were developed for determination of mesalazine (ME) and its two toxic impurities, 4-amino phenol (4AP) and salicylic acid (SA) without preliminary separation. The proposed methods are: ratio difference in the subtracted spectra (RDSS) {Method 1}, area under the curve (AUC) {Method 2} and TLC-densitometric {Method 3}. In method {1} combination of measuring the amplitude of the constant at 350 nm (using standard spectrum of 10 µg/mL ME as a divisor) and ratio difference in the subtracted ratio spectrum for determination of 4AP and SA using the ratio difference at 221...
2016: Chemical & Pharmaceutical Bulletin
Antonio Tursi, Giovanni Brandimarte, Francesco Di Mario, Maria L Annunziata, Mauro Bafutto, Maria A Bianco, Raffaele Colucci, Rita Conigliaro, Silvio Danese, Rudi De Bastiani, Walter Elisei, Ricardo Escalante, Roberto Faggiani, Luciano Ferrini, Giacomo Forti, Giovanni Latella, Maria G Graziani, Enio C Oliveira, Alfredo Papa, Antonio Penna, Piero Portincasa, Kjetil Søreide, Antonio Spadaccini, Paolo Usai, Stefanos Bonovas, Carmelo Scarpignato, Marcello Picchio, Piera G Lecca, Costantino Zampaletta, Claudio Cassieri, Alberto Damiani, Kari F Desserud, Serafina Fiorella, Rosario Landi, Elisabetta Goni, Maria A Lai, Flavia Pigò, Gianluca Rotondano, Giuseppe Schiaccianoce
BACKGROUND: Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification has been recently developed for patients suffering from diverticulosis and diverticular disease. AIMS: We assessed retrospectively the predictive value of DICA in patients for whom endoscopic data and clinical follow-up were available. METHODS: For each patient, we recorded: age, severity of DICA, presence of abdominal pain, C-reactive protein and faecal calprotectin test (if available) at the time of diagnosis; months of follow-up; therapy taken during the follow-up to maintain remission (if any); occurrence/recurrence of diverticulitis; need of surgery...
August 2016: United European Gastroenterology Journal
Panagiota Voukelatou, Elissavet Sfendouraki, Theodoros Karianos, Sofia Saranti, Dimitrios Tsitsimelis, Ioannis Vrettos, Andreas Kalliakmanis
Background. The presence of ulcerative colitis (UC) with no bowel symptoms, as fever of unknown origin (FUO), is uncommon. Objective. To describe the case of an 80-year-old woman who presented with fever, with a history of UC under treatment with mesalazine. Case Presentation. She was admitted due to fever lasting for 12 days with no associated symptoms. Seven years earlier, she was diagnosed with UC. After an extended workup for FUO that failed to reach the diagnosis, she underwent a gallium-67 scintigraphy...
2016: Case Reports in Medicine
Shoya Wada, Hideki Kumagai, Koji Yokoyama, Takane Ito, Akihiko Miyauchi, Saori Sakamoto, Tomoyuki Imagawa, Janyerkye Tulyeu, Masanori Tanaka, Takanori Yamagata
5-Aminosalicylic acid preparations have been used as first-line drugs for treatment of ulcerative colitis (UC). However, some patients with UC present with exacerbation of symptoms because of allergy to mesalazine. Diagnosis of mesalazine allergy in active UC may be challenging because its symptoms mimic those of UC. Here we describe a 13-year-old boy with mesalazine allergy who achieved remission when his medication was changed from mesalazine to salazosulfapyridine. During his clinical course mesalazine was prescribed twice, and on each occasion exacerbation of the symptoms occurred...
October 2016: Clinical Journal of Gastroenterology
Xin Zhao, Nan Li, YiMing Ren, Tao Ma, ChunLi Wang, Jun Wang, ShengYi You
BACKGROUND: Ulcerative colitis (UC) is a chronic and remitting inflammatory disease that is characterized by chronic idiopathic inflammation of the colon and bloody diarrhea. Currently drug treatment is the main intervention for patients with mild to moderate UC. Mesalazine (5-ASA) and beclomethasone dipropionate (BDP) have been widely used for the treatment of UC and have yielded satisfactory results. This study compared the effectiveness of 5-ASA and BDP in the treatment of UC. METHODS: The PubMed, Medline, SinoMed, Embase, and Cochrane Librinary databases were searched for eligible studies...
2016: PloS One
Aki Kawakami, Makoto Tanaka, Ryota Ochiai, Makoto Naganuma, Reiko Kunisaki, Keiko Kazuma
Current first-line treatment of ulcerative colitis consists of a combination of mesalazine enemas and oral mesalazine; however, many patients may discontinue mesalazine enemas. In this single-center, cross-sectional study, 165 outpatients with ulcerative colitis completed a self-administered questionnaire regarding the frequency of mesalazine enemas, difficulties in performing these enemas, and factors possibly associated with their discontinuation, as well as patient clinical and demographic characteristics...
August 3, 2016: Gastroenterology Nursing: the Official Journal of the Society of Gastroenterology Nurses and Associates
Shinichi Sameshima, Shinichiro Koketsu, Takashi Okuyama, Yawara Kubota, Yuko Ono, Tamaki Noie, Masatoshi Oya
BACKGROUND: Previous studies reported that nephrotic syndrome is associated with ulcerative colitis (UC) patients treated with mesalazine. Dysplasia associated with UC often develops into colorectal carcinoma. CASE PRESENTATION: A 17-year-old man was referred to our hospital, complaining of diarrhea and bloody stool. Total colonoscopy (TC) was performed and total-type UC was diagnosed. After treatment with mesalazine for 5 years, a low-grade dysplasia (LGD) was detected in the rectum by histological analysis of a biopsy sample...
2016: World Journal of Surgical Oncology
Amal Jamil Fatani, Fatima Salih Alrojayee, Mihir Yogeshkumar Parmar, Hatem Mustafa Abuohashish, Mohammed Mahboobuddin Ahmed, Salim Salih Al-Rejaie
The pathogenesis of ulcerative colitis (UC) has been associated with a weakened antioxidant capacity and increased inflammatory processes. Myrrh is traditionally used for the treatment of inflammatory diseases due to its antioxidant and anti-inflammatory properties. The present study aimed to evaluate the effects of myrrh on an experimental rat model of UC. UC was induced in rats using acetic acid (AA) after pre-treatment with myrrh (125, 250 or 500 mg/kg/day) or mesalazine (MES; 300 mg/kg/day) for 7 days. The levels of various inflammatory cytokines, prostaglandin E2 (PGE2) and nitric oxide (NO) in the rat colon tissues were assessed...
August 2016: Experimental and Therapeutic Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"